Cuprina Holdings Completes Reverse Stock Split and Seeks Nasdaq Hearing to Retain Listing

(SeaPRwire) –   SINGAPORE, May 29, 2026 — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical firm that develops and markets products for chronic wound care, infertility, medical waste recycling, and cosmeceuticals, today announced it finalized a reverse stock split on May 27, 2026. The Company has also requested a hearing before the Nasdaq Hearings Panel (the “Panel”) following a staff determination letter (the “Letter”) received on May 27, 2026, from Nasdaq’s Listing Qualifications Department (the “Staff”). The Letter informed the Company that, because it did not meet the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market (Nasdaq Listing Rule 5550(a)(2), the “Minimum Bid Requirement”), Nasdaq has decided (the “Determination”) to schedule the Company’s securities for delisting unless the Company appeals the Determination to a Panel.

The Company initially received a notice from Nasdaq (the “Notice”) on November 26, 2025. This Notice stated that the closing bid price for the Company’s securities over the prior 30 consecutive business days did not satisfy the Minimum Bid Requirement.

Pursuant to Listing Rule 5810(c)(3)(a), the Notice granted the Company a 180-calendar day grace period, ending on May 26, 2026, to restore compliance with the Minimum Bid Requirement. The Letter indicated the Company had not achieved compliance by that deadline.

If the Company does not appeal the Determination to the Panel by June 3, 2026, its securities will be suspended at market open on June 5, 2026. A Form 25-NSE will then be filed with the U.S. Securities and Exchange Commission (the “SEC”), which would delist and deregister the Company’s securities from Nasdaq. Submitting a hearing request will delay any suspension and the filing of Form 25-NSE until the Panel rules. The Company’s securities will remain trading on Nasdaq throughout these proceedings. Consequently, the Company submitted its hearing request to the Panel on May 28, 2026.

The Company proactively executed a share consolidation on May 27, 2026, which is anticipated to raise its bid price to meet the Minimum Bid Requirement. Cuprina is dedicated to preserving its Nasdaq listing and will issue material updates to shareholders as necessary.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-headquartered biomedical and biotechnology enterprise focused on creating and commercializing novel products for chronic wound management. We also have operations in the infertility, medical waste recycling, and health and beauty industries. Leveraging our biomedical research expertise, we source and apply natural materials to produce wound care products designed as medical devices that comply with international standards. For further details, visit https://www.cuprina.com.

FORWARD-LOOKING STATEMENTS

This press release contains certain statements concerning future expectations, plans, and prospects, along with other non-historical statements, that may be deemed “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, those regarding anticipated trading dates. Terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and comparable expressions aim to identify forward-looking statements, though not all such statements contain these words. Actual outcomes could differ significantly from those suggested by these forward-looking statements due to numerous critical factors, including: uncertainties surrounding market conditions and the finalization of any public offering, as well as other elements detailed in the “Risk Factors” segment of the preliminary prospectus submitted to the SEC. For these and other reasons, investors are advised against relying excessively on any forward-looking statements herein. Any forward-looking statements made in this release are relevant only as of its publication date. Cuprina Holdings (Cayman) Limited expressly disclaims any duty to revise any forward-looking statement, whether due to new information, future developments, or otherwise, unless mandated by law.

Cuprina Holdings (Cayman) Limited Investor Contact:
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5^th Floor
New York, New York 10036
Office: (646) 893-5835
Email: ir@skylineccg.com